CAISMOV24, a new human low-grade serous ovarian carcinoma cell line
Authors:
- Rodrigo Fernandes da SilvaRSRodrigo Fernandes da Silva
- Daniela Maira CardozoDCDaniela Maira Cardozo
- Gisele Olinto Libanio RodriguesGRGisele Olinto Libanio Rodrigues
- Caroline Natânia de Souza-AraújoCSCaroline Natânia de Souza-Araújo
- Natacha Azussa MigitaNatacha Azussa Migita
- Liliana Aparecida Lucci de Angelo AndradeLALiliana Aparecida Lucci de Angelo Andrade
- Sophie DerchainSDSophie Derchain
- José Andrés YunesJYJosé Andrés Yunes
- Fernando GuimarãesFGFernando Guimarães
Open Access
- 13 November 2017
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 756
Abstract
The spontaneous immortalization of primary malignant cells is frequently assigned to their genetic instability during in vitro culturing. In this study, the new epithelial ovarian cancer cell line CAISMOV24 was described and compared with its original low-grade serous ovarian carcinoma. The in vitro culture was established with cells isolated from ascites of a 60-year-old female patient with recurrent ovarian cancer. The CAISMOV24 line was assessed for cell growth, production of soluble biomarkers, expression of surface molecules and screened for typical mutations found in serous ovarian carcinoma. Additionally, comparative genomic hybridization was employed to compare genomic alterations between the CAISMOV24 cell line and its primary malignant cells. CAISMOV24 has been in continuous culture for more than 30 months and more than 100 in vitro passages. The cell surface molecules EpCAM, PVR and CD73 are overexpressed on CAISMOV24 cells compared to the primary malignant cells. CAISMOV24 continues to produce CA125 and HE4 in vitro. Although the cell line had developed alongside the accumulation of genomic alterations (28 CNV in primary cells and 37 CNV in CAISMOV24), most of them were related to CNVs already present in primary malignant cells. CAISMOV24 cell line harbored KRAS mutation with wild type TP53, therefore it is characterized as low-grade serous carcinoma. Our results corroborate with the idea that genomic alterations, depicted by CNVs, can be used for subtyping epithelial ovarian carcinomas. Additionally, CAISMOV24 cell line was characterized as a low-grade serous ovarian carcinoma, which still resembles its primary malignant cells.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/14777-1, 2014/07401-3, 2016/078224, 2011/17520-0)
This publication has 76 references indexed in Scilit:
- Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian massesBMC Cancer, 2013
- Histotype-specific copy-number alterations in ovarian cancerBMC Medical Genomics, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Rethinking ovarian cancer: recommendations for improving outcomesNature Reviews Cancer, 2011
- Detection of KRAS and BRAF Mutations in Colorectal CarcinomaThe Journal of Molecular Diagnostics, 2011
- The genesis and evolution of high-grade serous ovarian cancerNature Reviews Cancer, 2010
- Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade CarcinomasCancer Research, 2009
- Comprehensive analysis of HE4 expression in normal and malignant human tissuesLaboratory Investigation, 2006
- CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent mannerJournal of Experimental Medicine, 2005
- The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial OriginInternational Journal of Gynecological Pathology, 2004